BIOCON2023-10-012023-12-31 BIOCON2023-10-012023-12-31 BIOCON2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member BIOCON2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member BIOCON2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member BIOCON2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member BIOCON2023-12-31 BIOCON2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member BIOCON2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member BIOCON2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532523 BIOCON NOTLISTED Biocon Limited Equity 2023-04-01 2024-03-31 2024-02-08 2024-01-10 INR Millions Third quarter 17:00:00 18:50:00 2024-02-08 2024-02-08 Not applicable Single segment Pharmaceutical 2023-10-01 2023-12-31 Unaudited Standalone 5628000000.00 485000000.00 6113000000.00 2644000000.00 2000000.00 -161000000.00 1176000000.00 560000000.00 309000000.00 1254000000.00 5784000000.00 329000000.00 0.00 329000000.00 123000000.00 -34000000.00 89000000.00 0.00 240000000.00 0.00 0.00 0.00 0.00 240000000.00 -27000000.00 213000000.00 0.00 0.00 6003000000.00 5 0.20 0.20 0.00 0.00 0.20 0.20 Notes: 1. The unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2023 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee at their meeting held on February 7, 2024 and approved by the Board of Directors of the Company at their meetings held on February 8, 2024. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Due to size constraints, we are unable to provide full Notes in XBRL. Please refer Outcome of Board Meeying dated February 8, 2024, for full notes to the financial results for quarter ended 31.12.2023. Single segment 2023-04-01 2023-12-31 Unaudited Standalone 15947000000.00 1541000000.00 17488000000.00 8156000000.00 5000000.00 -1309000000.00 3355000000.00 1593000000.00 913000000.00 3633000000.00 16346000000.00 1142000000.00 145000000.00 1287000000.00 244000000.00 -12000000.00 232000000.00 0.00 1055000000.00 0.00 0.00 0.00 0.00 1055000000.00 -18000000.00 1037000000.00 0.00 0.00 6003000000.00 5 0.88 0.88 0.00 0.00 0.88 0.88 Less: Recovery of cost from co-development partners (net) 0.00 Other Expenses 1254000000.00 Less: Recovery of cost from co-development partners (net) -22000000.00 Other Expenses 3655000000.00 Items that will not be reclassified to profit or loss 2000000.00 Items that will not be reclassified to profit or loss -28000000.00 2000000.00 -28000000.00 0.00 -8000000.00 Items that will be reclassified to profit or loss -39000000.00 Items that will be reclassified to profit or loss 3000000.00 -39000000.00 3000000.00 -10000000.00 1000000.00